Free Trial

Ardelyx (ARDX) Competitors

Ardelyx logo
$4.60 +0.12 (+2.68%)
Closing price 04:00 PM Eastern
Extended Trading
$4.58 -0.02 (-0.54%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARDX vs. MRUS, ACLX, ACAD, SWTX, RARE, AAPG, PTGX, RNA, SRRK, and MLTX

Should you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Protagonist Therapeutics (PTGX), Avidity Biosciences (RNA), Scholar Rock (SRRK), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

Ardelyx vs. Its Competitors

Ardelyx (NASDAQ:ARDX) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Ardelyx has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Merus has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 96.1% of Merus shares are held by institutional investors. 4.8% of Ardelyx shares are held by insiders. Comparatively, 4.6% of Merus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ardelyx has a net margin of -14.86% compared to Merus' net margin of -506.73%. Ardelyx's return on equity of -34.45% beat Merus' return on equity.

Company Net Margins Return on Equity Return on Assets
Ardelyx-14.86% -34.45% -13.81%
Merus -506.73%-35.99%-29.83%

Ardelyx currently has a consensus price target of $10.89, suggesting a potential upside of 136.71%. Merus has a consensus price target of $84.64, suggesting a potential upside of 55.27%. Given Ardelyx's higher probable upside, equities research analysts plainly believe Ardelyx is more favorable than Merus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ardelyx
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.00
Merus
0 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.14

In the previous week, Ardelyx had 5 more articles in the media than Merus. MarketBeat recorded 8 mentions for Ardelyx and 3 mentions for Merus. Merus' average media sentiment score of 1.06 beat Ardelyx's score of 0.52 indicating that Merus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ardelyx
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Merus
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ardelyx has higher revenue and earnings than Merus. Ardelyx is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$333.61M3.30-$39.14M-$0.22-20.91
Merus$36.13M104.42-$215.33M-$4.08-13.36

Summary

Ardelyx beats Merus on 9 of the 17 factors compared between the two stocks.

Get Ardelyx News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARDX vs. The Competition

MetricArdelyxMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.07B$2.39B$5.51B$8.96B
Dividend YieldN/A1.80%5.25%4.02%
P/E Ratio-20.919.2628.0520.15
Price / Sales3.30771.14438.14127.85
Price / CashN/A161.3437.0657.97
Price / Book6.304.638.125.62
Net Income-$39.14M$31.26M$3.16B$248.50M
7 Day Performance9.79%6.81%4.40%5.54%
1 Month Performance22.34%4.31%4.09%7.52%
1 Year Performance-17.27%3.88%34.53%22.06%

Ardelyx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARDX
Ardelyx
4.4255 of 5 stars
$4.60
+2.7%
$10.89
+136.7%
-17.8%$1.07B$333.61M-20.9190Analyst Revision
MRUS
Merus
2.0831 of 5 stars
$52.60
-0.7%
$84.64
+60.9%
-6.1%$3.64B$54.73M-12.8937News Coverage
Positive News
ACLX
Arcellx
2.3156 of 5 stars
$65.85
+0.8%
$111.23
+68.9%
+19.3%$3.63B$107.94M-22.0280Positive News
ACAD
ACADIA Pharmaceuticals
4.6806 of 5 stars
$21.57
-2.5%
$27.88
+29.2%
+28.8%$3.61B$996.28M15.74510
SWTX
SpringWorks Therapeutics
1.6508 of 5 stars
$46.99
+0.0%
$52.57
+11.9%
N/A$3.54B$191.59M-13.78230Positive News
RARE
Ultragenyx Pharmaceutical
4.0671 of 5 stars
$36.36
-0.4%
$87.00
+139.3%
-5.0%$3.44B$590.69M-6.181,294News Coverage
AAPG
Ascentage Pharma Group International
N/A$39.38
-0.6%
N/AN/A$3.43B$134.35M0.00600News Coverage
PTGX
Protagonist Therapeutics
2.4513 of 5 stars
$55.27
-0.8%
$66.10
+19.6%
+43.3%$3.43B$434.43M73.69120News Coverage
Positive News
RNA
Avidity Biosciences
2.4751 of 5 stars
$28.40
-2.2%
$65.59
+130.9%
-24.3%$3.42B$10.90M-9.47190
SRRK
Scholar Rock
3.3049 of 5 stars
$35.42
-1.1%
$42.67
+20.5%
+335.1%$3.36B$33.19M-14.00140
MLTX
MoonLake Immunotherapeutics
1.9417 of 5 stars
$47.20
-0.7%
$74.50
+57.8%
+7.4%$3.02BN/A-20.522News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:ARDX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners